facebook twitter linkedin
  • images/stories/slider.png
  • images/stories/slider2.png
  • images/stories/slider3.png
  • images/stories/slider4.png

NEWS RELEASES

  • H3 Biomedicine and Selvita Reach First Research Milestone in Precision Cancer Medicines Collaboration

    Cambridge, MA and Krakow, Poland, 22 May 2014 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eas…

    Read More...

  • Selvita continues to improve financial results in Q1 2014

    Krakow, 13 May 2014 - Selvita, a drug discovery company listed on Warsaw Stock Exchange NewConnect market reported PLN0.57m net earnings in Q1 2014, compared to PLN1.0 m net loss in Q1 2013. This is the second quarter in a row that Selvita finished w…

    Read More...

  • Selvita will participate in the 15th Annual Drug Discovery Summit

      Krakow, 12 May 2014 - Selvita will participate the 15th Annual Drug Discovery Summit 2014 which will take place on 2-3 June 2014 in Geneva, Switzerland.   This summit brings together a host of senior level experts to discuss recent developmen…

    Read More...